Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2021-03-29 AGM Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting/Proxy Form 21 pages 824.4KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Annual General Meeting and Explanatory Statement' for Cyclopharm Limited, detailing the date and time of the AGM, instructions for virtual attendance, and a detailed agenda including resolutions to be voted on. It includes explanations of resolutions such as the Remuneration Report, re-election of a director, ratification of share placement, approval of a loan share plan, amendment of the constitution, and approval of non-executive director remuneration. The document also contains proxy voting instructions and voting exclusion statements. There is no actual financial data or full financial statements included, but rather information to inform shareholders about the AGM and the items to be discussed and voted on. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document is lengthy (15,000 characters) and comprehensive, consistent with a formal AGM notice and explanatory statement rather than a brief announcement or proxy solicitation only. Therefore, the correct classification is AGM Information (AGM-R).
2021-03-29 English
Annual Report to shareholders 82 pages 2.7MB
Annual Report Classification · 100% confidence The document is titled 'Cyclopharm Limited Annual Report 2020' and contains detailed sections typical of an annual report, including Summary Financials, Chairman's Letter, Managing Director's Review, Directors' Report, Auditor's Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, Independent Audit Report, Shareholder Information, and Corporate Directory. It includes comprehensive financial data for the full year ending 31 December 2020, management discussion of business strategy and performance, and audit-related content. The length of the document is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely a report publication announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent). FY 2020
2021-03-28 English
Appendix 4G 22 pages 462.5KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed disclosure related to corporate governance practices, including compliance with ASX Corporate Governance Council recommendations for the financial year ended 31 December 2020. The document includes a key to where governance disclosures can be found, references to the corporate governance statement, and compliance verification. It is not the corporate governance statement itself but a supplementary disclosure required by ASX listing rules. This type of document is specifically related to governance disclosures and internal rules rather than a full annual report or other financial filings. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is a substantive governance disclosure, not merely an announcement or certification.
2021-03-28 English
Change of Share Registry Details 1 page 80.7KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding a change in their shareholder registry service provider. It provides details on how shareholders can manage their holdings with the new provider. There is no financial data, no report attached or referenced as being published, and no mention of voting results, management changes, or other report types. The document is short (3014 characters) and is clearly an operational update related to shareholder services. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-25 English
Confirmation of Technegas USFDA Timetable 2 pages 125.5KB
Regulatory Filings Classification · 95% confidence The document is an announcement from Cyclopharm Limited providing an update on the US FDA timetable for approval of their New Drug Application (NDA) for Technegas. It discusses the expected dates for the FDA pre-approval audit, labeling requirements, and the goal date for NDA review completion. The document is relatively short (3860 characters) and serves as a status update on regulatory progress rather than containing financial data, detailed financial results, or comprehensive report content. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a certification or officer attestation. The document is an official company announcement about regulatory progress and timelines, fitting best into the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-11 English
Change of Director's Interest Notice - DH 2 pages 205.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in a director's relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and confirms no changes in contracts. The document is a formal notification of a director's personal share transactions, which aligns with the definition of Director's Dealing filings. The document length is 3454 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. Therefore, the appropriate classification is Director's Dealing (DIRS).
2021-03-07 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.